Please select the option that best describes you:
Do patient co-morbidities impact when you prescribe oral jak inhibitors?
Are you less likely to prescribe it for patients with dyslipidemia or autoimmune disease?
Answer from: at Community Practice
Great and pertinent question in our field. Autoimmunity doesn’t make me less likely to prescribe, actually more likely as there is plenty of case report and case series data on JAKi being used in a variety of autoimmune conditions. Certainly, dyslipidemia (think MACE), VTE risk, and malignancy...
Sign in or Register to read more
Answer from: at Community Practice
Not exactly the question you asked, but relevant recent study: Russell et al., PMID 37247942